Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Jul 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lineage Cell Therapeutics, Inc. (LCTX)
CIK: 0000876343
Period of Report: 2021-06-29

Reporting Person: ANDREWS DEBORAH J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-29	Common Shares, no par value	M	24720	$2.2	Acquired	34720	Direct
2021-06-29	Common Shares, no par value	S	19142	$2.93	Disposed	15578	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-29	Stock Option (right to buy)	$2.2	M	24720	Disposed	2021-06-30	Common Shares (24720)	Direct

Footnotes

F1: The price reported is a weighted average. These shares were sold in multiple transactions at a price of $2.93 or $2.935. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

F2: This option became exercisable in four equal quarterly installments after the date of grant on July 1, 2016